INONasdaqPharmaceutical PreparationsFiscal year ends December 31
INOVIO PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.00+0.01 (+1.00%)
Close on Oct 19, 2026
- Market cap
- $81.62M
- P/E (TTM)
- –
- Dividend yield
- –
INOVIO PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Grants and miscellaneous revenue from affiliated entity | – | – | – | – | – | $1.80K | $0 | $2.57M | $340.56K | – | – |
| Revenue under collaborative research and development arrangements with affiliated entities | – | – | – | $245.31K | $1.45M | $235.65K | $449.52K | $765.83K | $1.40M | – | – |
| Miscellaneous revenue, including from affiliated entities | – | – | – | – | – | $237.54K | $171.59K | $10.47M | $27.14M | – | – |
| Revenue under collaborative research and development arrangements, including from affiliated entities | – | – | – | $902.26K | $5.17M | $3.64M | $29.86M | $28.41M | $6.49M | – | – |
| Other revenue | – | – | – | $627.19K | $786.90K | $237.54K | $171.59K | – | – | – | – |
| Other revenue from affiliated entities | – | – | – | $0 | $0 | $1.80K | $0 | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Inovio Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.